Skip to main content

Reading data in migraine acute treatment studies: from clinical trials to reviews and meta-analyses


The huge amount of data regarding triptans in clinical practice provides a great opportunity to learn about their efficacy, tolerability and adverse events and offers to the clinician the background for the best treatment option in any patient, given that the patient is suitable for being treated with any of those compounds. A detailed clinical history is necessary in order to make a preliminary selection of triptan-suitable or -unsuitable migraine patients. Among the former, a secondary selection may be made, to recognise different attacks that can be successfully treated with different triptans, according to attack presentation and progression, within the same patient. Reading single original articles has become very difficult. Therefore, data are often presented in review form, which may be too partial or oriented. Systematic reviews or meta-analyses better serve to comment on data as they follow an analytic method that is based upon pooling data from original articles and comparing them using statistical aids.

Author information

Authors and Affiliations


Corresponding author

Correspondence to M. Gabriella Buzzi.

Rights and permissions

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Reprints and Permissions

About this article

Cite this article

Buzzi, M.G. Reading data in migraine acute treatment studies: from clinical trials to reviews and meta-analyses. J Headache Pain 7, 160–164 (2006).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Key words

  • Migraine
  • Triptans
  • Clinical trial
  • Meta-analysis